Prognostic value of changes in the expression of stem cell markers in the peripheral blood of patients with colon cancer

Padín-Iruegas,Maria-Elena; Herranz-Carnero,Michel; Aguin-Losada,Santiago; Brozos-Vazquez,Elena; Anido-Herranz,U.; Antunez-Lopez,Jose-Ramon; Ruibal-Morell,Alvaro; López-López,Rafael

doi:10.3892/or.2013.2368

Prognostic value of changes in the expression of stem cell markers in the peripheral blood of patients with colon cancer

Authors:
- Maria-Elena Padín-Iruegas
- Michel Herranz-Carnero
- Santiago Aguin-Losada
- Elena Brozos-Vazquez
- U. Anido-Herranz
- Jose-Ramon Antunez-Lopez
- Alvaro Ruibal-Morell
- Rafael López-López
View Affiliations

Affiliations: Department of Medical Oncology, University Hospital of Santiago de Compostela, La Coruña, Galicia, Spain, Molecular Oncology and Imaging Program, Molecular Imaging Group, IDIS, University Hospital of Santiago de Compostela, La Coruña, Galicia, Spain, Department of Pathology, University Hospital of Santiago de Compostela, La Coruña, Galicia, Spain, Department of Nuclear Medicine, Faculty of Medicine, University Hospital of Santiago de Compostela, La Coruña, Galicia, Spain
Published online on: March 27, 2013 https://doi.org/10.3892/or.2013.2368
Pages: 2467-2472

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells play an important role in carcinogenesis and resistance to treatment and may lead to metastasis. The isolation of circulating stem cells involves cell sorting based on the presence of cell surface markers. Many surface markers such as CD133, c-Kit, SOX, OCT4 and TWIST have been reported. In the present study, we determined the expression of different stem cell markers and their variation in expression at different stages of the treatment process. Samples of EDTA blood were collected from metastatic colorectal cancer patients, and circulating cancer stem cells were isolated for the analysis of the expression of stem cell markers using RT-PCR. These findings were correlated with the response to therapy. All statistical analyses were performed using the GraphPad Prism 5.03 software. Significant differences were found in the expression levels of the markers CD133, SOX2, OCT4 and TWIST1. No differences were found in c-Kit expression. Correlation in the expression levels of most of the markers was observed. Expression of CD133, OCT4, SOX2 and TWIST1 had a predictive value for colon cancer behavior. Evaluation of this stem cell gene expression panel may be useful for predicting the response during the process of treatment, and the relative easy access to samples facilitates this method. Moreover the correlation between CD133 and TWIST1 expression may be associated with tumor regrowth and metastatic relapse.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA and Edwards BK: SEER Cancer Statistics Review, 1975–2008. National Cancer Institute; Bethesda, MD: 2011
2	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar
3	Liao Y, Hu X, Huanq X and He C: Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biol Pharm Bull. 33:738–742. 2010. View Article : Google Scholar : PubMed/NCBI
4	Boman BM, Wicha MS, Fields JZ, et al: Symmetric division of cancer stem cells - a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther. 81:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
5	Boman BM, Fields JZ, Cavanaugh KL, Guetter A and Runquist OA: How dysregulated colonic crypt dynamics cause stem cell overpopulation and initiate colon cancer. Cancer Res. 68:3304–3313. 2008. View Article : Google Scholar : PubMed/NCBI
6	Morrison SJ and Kimble J: Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 441:1068–1074. 2006. View Article : Google Scholar : PubMed/NCBI
7	Johnston MD, Edwards CM, Bodmer WF, Maini PK and Chapman SJ: Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc Natl Acad Sci USA. 104:4008–4013. 2007. View Article : Google Scholar : PubMed/NCBI
8	Li CY, Li BX, Liang Y, et al: Higher percentage of CD133⁺ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med. 7:562009.PubMed/NCBI
9	Huff CA, Matsui WH, Smith DB and Jones RJ: Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 42:1293–1297. 2006. View Article : Google Scholar : PubMed/NCBI
10	Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
11	Shmelkov SV, Butler JM, Hooper AT, et al: CD133 expression is not restricted to stem cells, and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
12	Saigusa S, Tanaka K, Toiyama Y, et al: Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol). 23:323–332. 2011.PubMed/NCBI
13	Horst D, Kriegl L, Engel J, Kirchner T and Junq A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
15	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
16	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
17	Boman BM and Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol. 26:2795–2799. 2008. View Article : Google Scholar : PubMed/NCBI
18	Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
19	Zeki SS, Graham TA and Wright NA: Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:90–100. 2011. View Article : Google Scholar : PubMed/NCBI
20	Lau CK, Yang ZF and Fan ST: Role of stem cells in normal liver and cancer. Anticancer Agents Med Chem. 11:522–528. 2011. View Article : Google Scholar : PubMed/NCBI
21	Monzani E, Facchetti F, Galmozzi E, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI
22	Eramo A, Haas TL and De Maria R: Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene. 29:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
24	Maitland NJ and Collins AT: Cancer stem cells - A therapeutic target? Curr Opin Mol Ther. 12:662–673. 2010.PubMed/NCBI
25	Edling CE and Hallberg B: c-Kit - a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 39:1995–1998. 2007. View Article : Google Scholar : PubMed/NCBI
26	Niwa H, Miyazaki J and Smith AG: Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 24:372–376. 2000. View Article : Google Scholar : PubMed/NCBI
27	Looijenga LH, Stoop H, de Leeuw HP, et al: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 63:2244–2250. 2003.PubMed/NCBI
28	Tsukamoto T, Mizoshita T, Mihara M, et al: Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology. 46:649–658. 2005. View Article : Google Scholar : PubMed/NCBI
29	Jia X, Li X, Xu Y, et al: SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cells. J Mol Cell Biol. 3:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
30	Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ and Yang J: Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71:245–254. 2011. View Article : Google Scholar
31	Aktas B, Tewes M, Fehm T, Hausch S, Kimmig R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11:R462009. View Article : Google Scholar
32	Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD and Godfrey TE: Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem. 53:1206–1215. 2007. View Article : Google Scholar : PubMed/NCBI
33	Iinuma H, Watanabe T, Mimori K, et al: Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 29:1547–1555. 2011.PubMed/NCBI
34	Sher YP, Shih JY, Yanq PC, et al: Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res. 11:173–179. 2005.PubMed/NCBI
35	Ong CW, Kim LG, Kong HH, et al: CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 23:450–457. 2010. View Article : Google Scholar : PubMed/NCBI
36	Saigusa S, Tanaka K, Toiyama Y, et al: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
37	Li QQ, Xu JD, Wanq WJ, et al: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar
38	Friederichs J, von Weyhern CW, Rosenberg R, et al: Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. Langenbecks Arch Surg. 395:373–379. 2010. View Article : Google Scholar : PubMed/NCBI
39	Costelloe CM, Chuang HH, Madewell JE and Ueno NT: Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 28:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
40	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 7th edition. Wiley-Blackwell; New York: 2009